Mounjaro efekt: what tirzepatide actually does — and how to decide if it's right for you

How the dual-receptor effect differs from single-pathway medicines

Most GLP-1 medicines target one receptor. Tirzepatide hits two: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Activating GIP alongside GLP-1 appears to amplify the appetite-suppression signal and improve how the body handles glucose, the combination is why NICE's appraisal of tirzepatide noted that indirect comparisons favour it over semaglutide at equivalent treatment stages, a finding later supported by the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025, which showed greater average weight reduction with tirzepatide than with semaglutide 2.4 mg over 72 weeks.

In practical terms, the GIP component also modulates gastric emptying slightly differently to semaglutide, some people find the nausea profile easier to manage, though individual responses vary and a prescriber should be your guide on that. You can read a fuller breakdown of the mechanism on the tirzepatide overview page.

The key point: the dual mechanism is not a marketing phrase. It is why the clinical trial results differ from older single-agonist medicines, and it is the biological reason NICE chose to recommend tirzepatide separately under its own appraisal.

What the efekt looks like month by month, and why the starting dose feels underwhelming

The 2.5 mg starting pen exists to settle your system, not to produce weight loss. Its job is to let your gut adapt to the new signalling before the prescriber moves you to a dose with meaningful therapeutic effect. People who expect results in the first four weeks and don't see them sometimes conclude the medicine isn't working, that's the wrong read. Appetite suppression becomes more noticeable from 5 mg upward, and the 5 mg dose guide covers what to expect at that stage.

Weight loss in the trials was not linear. Most participants saw the steepest rate of change between weeks 12 and 36, with the curve flattening toward a plateau as the body adapts. The 20–21% average at 15 mg in SURMOUNT-1 was measured over 72 weeks, roughly 17 months. Expecting that result in three months is the fastest route to disappointment.

A practical habit worth building: once a week, at the same time and in similar clothing, step on a scale and note the number. Over 28-day blocks the direction of travel tells you more than any single weigh-in. That's under a minute and removes the noise of daily fluctuation. Our 2.5 mg starting guide has more detail on what to track in the early weeks.

Side effects, and when the efekt crosses into something to act on quickly

Nausea is the most commonly reported side effect. For most people it peaks in the days after a dose increase and fades as the body adjusts, eating smaller portions, keeping food plain and staying well hydrated helps. Loose stools, constipation, indigestion and fatigue also appear in trial data, typically mild to moderate and transient. The Mounjaro side effects page covers the full profile in detail.

There are symptoms that need urgent medical attention rather than waiting. Severe, persistent abdominal pain that radiates toward the back (with or without vomiting) should prompt a same-day call to your GP or 111. The MHRA highlighted acute pancreatitis as a known, infrequent but serious risk for GLP-1 medicines in a January 2026 Drug Safety Update. Gallbladder symptoms, signs of dehydration from prolonged vomiting, or any allergic reaction also warrant prompt review.

If you notice side effects you're unsure about, the Yellow Card scheme at yellowcard.mhra.gov.uk allows patients to report suspected reactions directly to the MHRA, that feedback shapes future safety guidance for everyone on these medicines.

One situation that catches people off guard: if you take the oral contraceptive pill and are starting tirzepatide, NHS guidance advises adding a non-oral contraceptive method for the first four weeks of treatment and for four weeks after each dose increase. Tirzepatide's effect on gastric emptying can reduce pill absorption. The guide to tirzepatide and hormonal changes touches on related questions.

Who the clinical evidence applies to, and the eligibility question the prescriber answers

The licensed indication covers adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK guidance. NICE's appraisal TA1026 sets NHS eligibility criteria that are stricter than the licence, for a clear breakdown of the NHS phased rollout versus private routes, the Mounjaro overview covers both.

The licence and the NICE criteria are starting points. The prescriber looks at your full picture: current medicines, medical history, contraindications, what you've tried before. A history of medullary thyroid carcinoma, certain pancreatic conditions or active eating disorders changes the calculus. BMI alone does not determine approval.

If cost is part of your decision, the cost context guide explains what private prices typically include and why the cheapest listing is the wrong number to anchor on when assessing a prescription medicine. For a broader look at all licensed weight-loss options, the treatment overview sets out what is available in the UK and what distinguishes each one.